CD19 and cancer: We next sought to demonstrate the direct application of CD19+ SCASA yeast cells in characterizing responses of different CAR designs, employing 50 distinct yeast-based stimulatory conditions of antigen densities and target-to-effector cell ratios to simulate different cancer scenarios.